Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640156 | 0.85 | GRM5 (0.41) | GRM5MAPK14CYP2C9HDAC6KAT8 | |
| SCHEMBL6640151 | 0.85 | GRM5 (0.41) | GRM5MAPK14CYP2C9HDAC6KAT8 | |
| SCHEMBL6835075 | 0.83 | GRM5 (0.38) | GRM5MAPK14HDAC6KAT8MEN1 | |
| SCHEMBL6638121 | 0.78 | KMT2A (0.49) | KMT2A | |
| SCHEMBL8393362 | 0.68 | SMN1; SMN2 (0.68) | HDAC6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6638634 | 0.67 | KDM4E (0.56) | GRM5KMT2ASMN1; SMN2 | |
| SCHEMBL24834873 | 0.66 | GRM5 (0.75) | GRM5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24448890 | 0.65 | GRM5 (0.55) | GRM5MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8391563 | 0.65 | SMN1; SMN2 (0.73) | HDAC6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6637781 | 0.65 | SMN1; SMN2 (0.54) | MAPK14HDAC6MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | GRM5 2788/4885MAPK14 3605/4885CYP2C9 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.